Inserm presentation
Contents

• Address major biomedical research challenges

• Take action to improve the health of all

• Disseminate knowledge for the benefit of all
Address major biomedical research challenges
Address major biomedical research challenges

Be a reference in biomedical research

**In Europe and worldwide**
- 6,750 international cooperations with more than 100 countries (*in 2020*)
- 1 thematic coordination program, 12 new first-step projects and 12 new European and international research projects or networks (*in 2022*)
- 2 joint research units abroad

**14,292 staff**
- 5,077 civil servants (2,174 researchers, ATIP-Avenir contracts included)
- 3,325 contract staff and temporary workers (incl. ATIP-Avenir contracts)
  > 50 ATIP-Avenir contracts
- 5,890* teacher-researchers and hospital teachers

**A budget of €1,161 million**
- €701 million from government subsidies
- €460 million from internal resources

**In France**
- 256 research units
- 35 clinical investigation centers
- 45 service units

**Patents and licenses**
- A portfolio of 2,153 patent families
- 62 new license agreements signed
- 360 R&D partnerships

* Temporary 2022 figure
• Address major biomedical research challenges

Be a reference in biomedical research (2)

In Europe
• No. 1 academic applicant in the biomedical sector in Europe
• No. 2 European applicant in the biotechnology sector and No. 3 in the pharmaceutical sector
• 396 H2020 contracts, 149 within the Health challenge and 34 coordinated by Inserm (No. 1 in Europe)
• 97 ERC grant recipients
• 53 Marie Skłodowska-Curie individual grants and participation in 44 innovative training networks (ITN)

Close dialogue
with over 500 patient organizations for
• participatory research
• meetings and debates between patients and researchers

13,976 original articles
• Address major biomedical research challenges

Make changes to adapt

1964
Inserm is created

1983
Public scientific and technological institute, entirely dedicated to human health and biomedical research
Placed under the joint authority of the French Ministries of Health and Research

2009
Inserm, following reform, ensures the strategic, scientific and operational coordination of biomedical research
Aviesan, the French National Alliance for Life Sciences and Health, is created

2011

2014
Inserm establishes its 2021-2025 Objectives, resources and performance contract

2019
Inserm establishes its 2025 Strategic plan with the French State
Inserm celebrates its 50th anniversary

2022
Inserm establishes its 2021-2025 Objectives, resources and performance contract
• Address major biomedical research challenges

Our organization

Thematic Institutes

- Neurosciences, Cognitive Sciences, Neurology, Psychiatry
- Cancer
- Immunology, Inflammation, Infectious Diseases and Microbiology
- Pathophysiology, Metabolism, Nutrition
- Public Health
- Health Technologies
- Molecular and Structural Basis of Living Organisms
- Cell Biology, Development and Evolution
- Genetics, Genomics and Bioinformatics

Divisions

- Financial Affairs
- Legal Affairs
- Program Assessment and Follow-Up
- Scientific Information and Communication
- Partnership and External Relations
- Human Resources
- Information Systems
- Chief Accounting Department

Regional Offices

- Île-de-France (4)
- Auvergne-Rhône-Alpes
- Est
- Grand Ouest
- Occitanie Méditerranée
- Occitanie Pyrénées
- Nord-Ouest
- Nouvelle-Aquitaine
- Provence, Alpes, Côte d’Azur and Corsica

Inserm
Address major biomedical research challenges

Our presence in France

256 Research units

45 Service units

35 Clinical investigation centers
• Address major biomedical research challenges

Our presence in France

83% of Inserm strengths

13 research universities in which Inserm invests more than €10M each year
Our main partners

- **34** universities
- A key partner of **13** research universities in which Inserm invests more than €10M each year
- On **14** Idex and I-sites, Inserm invests **78%** of its resources
- Research units in **30** teaching hospitals
- Founding members of Aviesan alongside Inserm: CEA / CNRS / INRAE / INRIA / Institut Pasteur / IRD / CPU / CHRU and the associate members
- Other alliances: AllEnvi, Allistène, Athéna
- Industry: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi…
- Foundations and associations: Fondation Bettencourt Schueller, FRM…
- European and international academic institutions: Helmholtz…
• Address major biomedical research challenges

Our presence in Europe

• Research teams: informal **scientific cooperation** with their partners
• Institutional **partnership agreements** and **specific collaborative networks** in Europe: 2 European laboratories within a single thematic coordination program, 13 leading international research projects (IRP) and 2 within a single international research network (IRN)

![Map of Europe showing research units and partnerships]

- Research unit abroad
- Thematic Coordination Program
- International Research Projects
- International Research Network

- **Germany:** Munich, Ulm
- **Switzerland:** Zurich, Bern
- **Netherlands:** Maastricht, Amsterdam
- **Belgium:** Brussels (2), Antwerp, Wilrijk, Louvain-la-Neuve
- **Portugal:** Porto
- **United Kingdom:** London, Heidelberg, Planneg, Nottingham
- **Athens, Greece:**

---

**Inserm**
Our presence in the world

- Research teams: informal **scientific cooperation** with their partners
- Institutional **partnership agreements** and **specific collaborative networks** outside Europe: 2 non-European laboratories within a single thematic coordination program, 18 leading international research projects (IRP) et 1 within an international research network (IRN)
Take action to improve the health of all
Take action to improve the health of all

Our missions for health

- Produce and disseminate knowledge nationally and internationally
- Play a major role in the national coordination of health research
- Provide scientific expertise and support for science-based policy in health
- Create value from discoveries and their applications
- Initiate, develop and coordinate biomedical research of excellence
Our fields of activity and expertise

- Fundamental research
- Clinical and preclinical trials
- Cohorts and epidemiological studies
- Provision of expertise and contribution to public health and research policy
- Biomedical research infrastructure
- Technology transfer

- Take action to improve the health of all
Cohorts and epidemiological studies

- **EpiCOV**: 130,000 volunteers for research on SARS-CoV-2
- **ELFE**: 20,000 children born in 2011. Longitudinal study from birth to adult age
- **Constances**: 200,000 subjects representative of the French population, aged 18 to 69 years + a biobank of 100,000 subjects
- **RaDiCo**: over 5,000 people with rare diseases in 12 cohorts
- **Epidemiologie-France portal**: French health database catalogue
  > epidemiologie-france.aviesan.fr
- **CépiDc**: Epidemiology center on the medical causes of death
  > cepidc.inserm.fr
- **Orphanet**: Portal for rare diseases and orphan drugs
  > orpha.net

**Over 1.6 million people** (2% of the French population) participating in Inserm cohorts

- Over 5,000 people with rare diseases in 12 cohorts...
A continuum from basic to clinical, therapeutic, and public health research

- Basic research
- Preclinical Studies
  - Proof of concept
- Phases I, IIa, IIb, III
- Phase IV

- 256 research units
- National research infrastructures
- 35 clinical research centers
- About 90 cohorts & large scale studies
• Take action to improve the health of all

Value creation activities which are bearing fruit

- **2,153** patent families portfolio
- **147** new patent families in 2021
- An annual budget of **€1.6 M** to fund project maturation or proof of concept
- A maturation budget reaching **€21.7 M** invested in 336 projects since 2009
- **€445 M** industrial partnerships since 2010 (patents, research contracts)
- **€6-12 M** per year from licensing agreements
- Over **400** technologies and research tools available for licensing
- Strategic alliances with, for example: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi
- 10 start-up created each year via Inserm Transfert (Inserm’s subsidiary)
- Partnerships with SATTs
Inserm & Inserm Transfert in EPO rankings

- No. 3 European applicant in the pharmaceutical sector (in the Top 3 since 2015)*
- No. 2 European applicant in the biotechnology sector (3rd year)*
- No. 1 European research academic institution in the biomedical sector*
- 2,153 patent families as of 31/12/2021

* European Patent Office (EPO) 2021 rankings
Inserm Transfert: partnering with industries

**SOME OF OUR INDUSTRIAL PARTNERS:** Privileged partner of major industrials, mid-size, SME, involved in human health, at the international level
• Take action to improve the health of all

Inserm spin-offs based on inventors as drivers
Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- the first prenatal diagnostic tests;
- understanding the HLA system and the ensuing immune reactions;
- the first in vitro fertilization;
- identification of HIV;
- radiotherapy for cancer;
- the first skin graft;
- deep brain stimulation in the treatment of Parkinson’s disease;
- gene therapy…
Disseminate knowledge for the benefit of all
Inserm fulfills its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.
Towards research in partnership with patient organizations and civil society collectives

- Promote meetings and direct dialogue between researchers and collectives
- Act for the structuring, coordination and animation of participatory research projects
- Help to better take into account these projects in the assessment of researchers and structures
- Facilitate access to scientific information for society
Our presence in the service of public information

- **inserm.fr**
  - 13,204,000 sessions
  - 110,000 followers

- **LinkedIn**
  - 110,000 followers

- **Twitter**
  - 155,000 followers

- **Facebook**
  - 49,000 followers

- **Instagram**
  - 11,000 followers

- **YouTube**
  - 270,000 followers

- **Public events**
  - + than 2 millions participants and views

- **Patient organization training seminars**
  - 1,100 participants *

- **Canal Détox information videos and articles**
  - + than 1.2 million views

* 2020 figures